Cerevel Therapeutics Holdings Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  7598.9

• Ticker

  CERE.O

• ISIN

  US15678U1280

• IPO date

  2020-06-05

• Availability on Russian exchanges

  Yes

• Reporting for

  2024-02-27

• Date fact. publication of reports

  2023-12-31

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with chemistry and central nervous system (CNS), receptor pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. The Company’s product candidate includes CVL-231, Darigabat, Tavapadon, CVL-871 and CVL-936. The Company’s product candidate CVL-231 for the treatment of schizophrenia. Its Darigabat for the treatment of both epilepsy and anxiety. Its Tavapadon is a dopamine D1/D5 partial agonist for the treatment of early- and late-stage Parkinson’s disease. Its product candidate CVL-871 for the treatment of dementia-related apathy. Its CVL-936 for the treatment of substance use disorder (SUD).